The purpose of this study is to evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes who are not achieving glycemic targets.

Inclusion Criteria:

• Has HbA1c >7.0% and <=10.5%
• Has a body mass index (BMI) >=25 kg/m2 and <=45 kg/m2
• Has received insulin glargine for 3 months prior to study start and has been on a stable dose for 1 month prior to study start
• If taking oral antidiabetic agents, has been on a stable dose for at least 2 months

Exclusion Criteria:

• Has been previously treated with Symlin/pramlintide (or has participated in a Symlin/pramlintide clinical study)
• Has received any investigational drug within 1 month of screening